An interventional study of Amisulpride Injection and Dexamethasone (intravenous) in Nausea and Vomiting, Postoperative, sponsored by Sir Run Run Shaw Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Sir Run Run Shaw Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing amisulpride in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Amisulpride · Postoperative Nausea and Vomiting.
Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 2 with no phase, and was the 10th registered.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
Browse Postoperative Nausea and Vomiting studies →2 of the 11 studies testing amisulpride in Postoperative Nausea and Vomiting are open now, in 1 country. Recruiting first, the newest first:
Qianfoshan Hospital
Ages 18–75
By country, each count listing its studies:
Amisulpride: first FDA approval 2020 (BARHEMSYS). What it is approved for, and how studies give it, is on its page →
Of the 66 Postoperative Nausea and Vomiting studies recruiting now, 22 (33%) set no upper age limit and 38 (58%) stop at 75 or younger; 15 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7
First in 2012; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 212 is above the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.
Median enrollment 453 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
Sir Run Run Shaw Hospital is the lead sponsor of 136 studies on the registry; 73 are open to participants now.
Sir Run Run Shaw Hospital has 1 study filed under Postoperative Nausea and Vomiting — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Objectives To evaluate the preventive effect of TEAS on PONV in patients undergoing gynecological laparoscopic surgery, compared with sham stimulation.
To explore the synergistic effect of dexamethasone or amisulpride when combined with TEAS, and to optimize PONV prevention strategies.
To assess the impact of multimodal intervention on postoperative recovery quality, length of hospital stay, and patient satisfaction.
To evaluate the safety of the combined interventions and record any adverse events.
Study Design Design type: 2×2 factorial, randomized, double-blind (participants, outcome assessors, and data analysts blinded to group assignment).
Randomization: 1:1:1:1 allocation using an online randomization tool.
3.1 Study Groups Group Intervention A TEAS + Dexamethasone B TEAS + Amisulpride C Sham stimulation + Dexamethasone D Sham stimulation + Amisulpride 3.2 Participants Inclusion criteria: Age 18-65 years; ASA physical status I-II; scheduled for elective gynecological laparoscopic surgery (e.g., ovarian cystectomy, myomectomy) under general anesthesia; willing to provide informed consent.
Exclusion criteria: Severe cardiac, hepatic, renal, or pulmonary disease; allergy or skin disease at TEAS application site; Receipt of antiemetics within 24 h before surgery; Implanted cardiac pacemaker, cardioverter-;pregnancy or lactation; vulnerable populations (e.g., critically ill, psychiatric disorders, cognitive impairment, illiteracy); any condition deemed unsuitable by the investigator.
3.3 Interventions A wearable transcutaneous electrical acupoint stimulation (TEAS) wristband will be applied to the P6 (Neiguan) acupoint on the dominant upper extremity. The P6 acupoint is located approximately 3-5 cm proximal to the distal wrist crease, between the tendons of the flexor carpi radialis and palmaris longus. The device integrates the stimulating electrodes within the wristband and does not require external adhesive electrodes.
TEAS or sham stimulation will be administered at three time points: 30 minutes before surgery and 24 and 48 hours after surgery, with each session lasting 30 minutes.
Dexamethasone 5 mg (off-label for PONV; approved for inflammatory/allergic conditions).
Amisulpride 5 mg.
3.4 Outcome Measures
Primary outcomes (0-48 h postoperatively):
PONV incidence (proportion of patients with nausea, vomiting, or retching). PONV severity (0 = none, 1 = nausea only, 2 = vomiting/retching, 3 = refractory nausea/vomiting).
Secondary outcomes:
Recovery quality: time to first flatus, first ambulation, hospital stay, bowel function recovery.
Patient satisfaction: Visual Analogue Scale (VAS, 0-10) and QoR-15 score (0-150).
Rescue antiemetic use. Management needs for severe PONV. Postoperative pain (VAS at rest and on movement) and opioid consumption. Device-related adverse events (skin irritation, burning, allergy). Drug-related adverse events (e.g., hyperglycemia, hypotension, headache, dizziness, QT prolongation).
Intraoperative hemodynamics and postoperative complications (e.g., infection, shivering, urinary retention).
3.5 Follow-up Schedule Postoperative day 1 (24 h): PONV assessment, time to first flatus and ambulation.
Postoperative day 2 (48 h): PONV incidence/severity, rescue medication. At discharge: Satisfaction, hospital stay (via in-person or telephone follow-up).
Sample Size Calculation Assumptions: PONV incidence 50% in control groups, 30% in TEAS groups; two-sided α = 0.05; power = 80%.
Each main effect level requires \~93 patients. For a 2×2 factorial design with 1:1:1:1 allocation, this translates to 47 patients per group (total 188). Accounting for a 10% dropout rate, final sample size = 212 patients (53 per group).
Data Management and Confidentiality Electronic Data Capture (EDC) system with unique coding (no direct identifiers).
Access restricted to authorized research team members.
Amisulpride-related AEs (headache, dizziness, constipation/diarrhea, QT prolongation, allergic reactions).
TEA-related AEs (local skin discomfort, redness, itching, rare blisters or mild burns).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm receive both transcutaneous electrical acupoint stimulation (TEAS) and dexamethasone. TEAS: Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator. Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation. The highest well-tolerated intensity will then be maintained for treatment. Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
Drug: Dexamethasone (intravenous) · Device: Transcutaneous electrical acupoint stimulation (TEAS)
Participants in this arm receive both transcutaneous electrical acupoint stimulation (TEAS) and amisulpride. TEAS: Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator. Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation. The highest well-tolerated intensity will then be maintained for treatment. Amisulpride: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
Drug: Amisulpride Injection · Device: Transcutaneous electrical acupoint stimulation (TEAS)
Participants in this arm receive both sham transcutaneous electrical acupoint stimulation (TEAS) and dexamethasone. Sham stimulation: Electrodes are placed at the P6 acupoint (inner forearm, approximately 2 cun proximal to the wrist crease) for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. The device is attached but does not deliver any electrical output (no current). Participants are blinded to the stimulation status. Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
Drug: Dexamethasone (intravenous)
Participants in this arm receive both sham transcutaneous electrical acupoint stimulation (TEAS) and amisulpride. Sham stimulation: Electrodes are placed at the P6 acupoint (inner forearm, approximately 2 cun proximal to the wrist crease) for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. The device is attached but does not deliver any electrical output (no current). Participants are blinded to the stimulation status. Amisulpride: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
Drug: Amisulpride Injection
Amisulpride:Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator. Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation. The highest well-tolerated intensity will then be maintained for treatment.
PONV incidence within 48 hours postoperatively
Proportion of patients experiencing nausea, vomiting, or retching.
Time frame: within 48 hours
PONV severity
Assessed using a 4-grade scale: Grade 0 = no nausea or vomiting Grade 1 = nausea only Grade 2 = vomiting or retching Grade 3 = refractory nausea and vomiting
Time frame: within 48 hours
Nausea
The number of nausea episodes recorded after surgery
Time frame: 24 hours and 48 hours after surgery
Vomiting
The number of vomiting episodes recorded after surgery.
Time frame: 24 hours and 48 hours after surgery
Retching
The number of retching episodes recorded after surgery.
Time frame: 24 hours and 48 hours after surgery
Time to first flatus
The time from the end of surgery to the first passage of flatus after transfer from the post-anesthesia care unit (PACU) to the ward.
Time frame: Up to 48 hours after surgery
Time to first ambulation
The time from the end of surgery to the patient's first out-of-bed activity.
Time frame: Up to 48 hours after surgery
Length of hospital stay
Duration of postoperative hospitalization, measured in days.
Time frame: Up to 7 days after surgery
Bowel function recovery
Assessed by the time of defecation.
Time frame: Up to 48 hours postoperatively
Quality of recovery (QoR-15)
QoR-15 questionnaire score ranging from 0 to 150, covering 15 dimensions including physical comfort, emotional state, and psychological well-being.
Time frame: Up to 24 hours postoperatively
Rescue antiemetic use
The type and number of rescue antiemetic medications required when a patient experiences PONV postoperatively.
Time frame: Up to 48 hours postoperatively
Number of Participants Requiring Management for Severe PONV
Number of participants with severe postoperative nausea and vomiting, such as persistent vomiting or retching, requiring urgent additional amisulpride or other interventions.
Time frame: Up to 48 hours postoperatively
Postoperative pain (VAS at rest)
Pain intensity measured at rest using a Visual Analogue Scale (0 = no pain, 10 = worst possible pain).
Time frame: Assessed at 24, 48, and 72 hours after surgery
Postoperative pain (VAS on movement)
Pain intensity measured during movement (e.g., turning, coughing) using a Visual Analogue Scale (0 = no pain, 10 = worst possible pain).
Time frame: Assessed at 24, 48, and 72 hours after surgery
Postoperative opioid consumption
Total amount of opioids consumed after surgery.
Time frame: Assessed at 48 hours after surgery.
Device-related adverse events
Adverse events associated with TEAS or sham stimulation, including local skin irritation, burning sensation, redness, itching, blistering, or mild burns at the electrode site.
Time frame: Assessed after TEAS treatment before surgery, 24 hours after surgery, and 48 hours after surgery.
Drug-related adverse events
Adverse events related to dexamethasone or amisulpride, including but not limited to headache, dizziness, constipation, diarrhea, facial flushing, QT prolongation, allergic reactions (rash, dyspnea, hypotension), transient hyperglycemia, and blood pressure fluctuations.
Time frame: Assessed at 24 and 48 hours after surgery.
Proportion of Participants Receiving Intraoperative Vasoactive Drugs
Proportion of participants who received any vasoactive medication during surgery.
Time frame: Intraoperative period
Postoperative complications
Occurrence of complications after surgery, including infection, shivering, and urinary retention.
Time frame: Up to 7 days after surgery
Headache
Number of patients with postoperative headache
Time frame: 24 hours and 48 hours after surgery
Dizziness
Number of patients with postoperative dizziness
Time frame: 24 hours and 48 hours after surgery
Plan to share: No — No participant consent for data sharing Ethical approval does not permit it Chinese regulations restrict sharing of sensitive health data No data sharing agreement or infrastructure in place
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Oct 2026, 3 months later.
Of 181 non-industry interventional studies with no phase under Postoperative Nausea and Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 3 months is below that.
Counting every sponsor, half of 181 studies reached it within 13 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amisulpride · Dexamethasone
Postoperative Nausea and Vomiting →